Affordable Access

deepdyve-link
Publisher Website

Noteworthy prognostic value of phospholipase C delta genes in early stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy and potential molecular mechanisms.

Authors
  • Zhou, Xin1
  • Liao, Xiwen1
  • Wang, Xiangkun1
  • Huang, Ketuan1
  • Yang, Chengkun1
  • Yu, Tingdong1
  • Han, Chuangye1
  • Zhu, Guangzhi1
  • Su, Hao1
  • Han, Quanfa1
  • Chen, Zijun1
  • Huang, Jianlv1, 2
  • Gong, Yizhen3
  • Ruan, Guotian3
  • Ye, Xinping1
  • Peng, Tao1
  • 1 Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China. , (China)
  • 2 Department of Hepatobiliary Surgery, The Third Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China. , (China)
  • 3 Department of Colorectal and Anal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China. , (China)
Type
Published Article
Journal
Cancer Medicine
Publisher
Wiley
Publication Date
Dec 06, 2019
Identifiers
DOI: 10.1002/cam4.2699
PMID: 31808619
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The purpose of this investigation was to explore the prognostic value of phospholipase C delta (PLCD) genes in early stage pancreatic ductal adenocarcinoma (PDAC) and its potential molecular mechanisms. The prognostic value of PLCD genes in early stage PDAC was assessed using the Kaplan-Meier method and multivariate Cox proportional hazards regression model. Genome-wide correlation analysis was performed on PLCD3 to identify the highly correlated genes in the transcriptome. Then, PLCD3 and these correlated genes together underwent a bioinformatics analysis to elucidate the potential molecular biological functions of PLCD3 in PDAC. PLCD1 and PLCD3 are significantly overexpressed in PDAC. In PDAC patients, PLCD3 is overexpressed in certain groups of people with a history of alcoholism (P = .032). High expression of PLCD3 was found to be associated with lower overall survival (OS) of patients with early stage PDAC (P = .020; adjusted P = .016). A combination of PLCD3 and clinical variables was able to better predict the outcome of patients with early stage PDAC. These clinical variables are histological grade (P = .001; adjusted P = .001), targeted molecular therapy (P < .001; adjusted P < .001), radiation therapy (P = .002; adjusted P = .039), and residual resection (P = .001; adjusted P = .002). The bioinformatics analysis revealed that PLCD3 is associated with angiogenesis, intracellular signal transduction, and regulation of cell proliferation. In conclusion, PLCD3 may be a potential prognostic biomarker for early stage PDAC. © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Report this publication

Statistics

Seen <100 times